Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT), an eyecare technology company specializing in innovative interventional technologies, has announced its participation in the 24th Annual Needham Healthcare Conference. The virtual event will feature a presentation by the company's management on April 8, 2025, at 12:45 PM PT / 3:45 PM ET.
Investors and interested parties can access both the live and archived versions of the fireside chat through the company's investor relations website at investors.sightsciences.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SGHT declined 0.56%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually.
Sight Sciences’ management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2025 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
FAQ
When is Sight Sciences (SGHT) presenting at the Needham Healthcare Conference 2025?
How can investors watch Sight Sciences' (SGHT) Needham Conference presentation?
Is the 2025 Needham Healthcare Conference where SGHT is presenting in-person or virtual?
What type of presentation will SGHT deliver at the 2025 Needham Conference?
